Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas

Yoshito Tomimaru, Yutaka Takeda, Mitsuaki Tatsumi, Tonsok Kim, Shogo Kobayashi, Shigeru Marubashi, Hidetoshi Eguchi, Masahiro Tanemura, Toru Kitagawa, Hiroaki Nagano, Koji Umeshita, Kenichi Wakasa, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas presents in various histopathological stages from benign to malignant lesions. The differentiation between benign and malignant IPMN is important in order to determine the treatment of the patients. However, preoperative differentiation remains difficult. The aim of this study was to assess the utility of 2-[ 18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in preoperative differentiation of benign and malignant IPMN of the pancreas. In the present study we prospectively investigated 29 patients who underwent CT, FDG-PET, and surgery for IPMNs, followed by histopathological examination. The maximum standardized uptake value (SUVmax) was determined on FDG-PET, and differentiation of benign from malignant IPMN was tested using various SUVmax cut-off levels and various parameters derived from the CT. SUVmax was found to be significantly higher in malignant IPMNs (4.7±3.0) than that in benign IPMNs (1.8±0.3, P=0.0011). SUVmax values correlated with the histopathological types of IPMN (adenoma/borderline lesion/carcinoma in situ/invasive carcinoma) (Spearman rank correlation 0.865, P<0.0001). The specificity, sensitivity and accuracy values were best for SUVmax of 2.5 (100, 93, and 96%, respectively). The combination of mural nodule, detected on CT, and SUVmax of 2.5 offered the best diagnosis of malignant IPMN. These results suggest that FDG-PET is useful for differentiation of malignant IPMN of the pancreas, and that it should be performed in combination with other conventional imaging modalities.

Original languageEnglish
Pages (from-to)613-620
Number of pages8
JournalOncology Reports
Volume24
Issue number3
DOIs
Publication statusPublished - Sep 2010
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Pancreatic Neoplasms
Positron-Emission Tomography
Deoxyglucose
Differential Diagnosis
Neoplasms
Carcinoma in Situ
Adenoma
Carcinoma
Sensitivity and Specificity
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. / Tomimaru, Yoshito; Takeda, Yutaka; Tatsumi, Mitsuaki; Kim, Tonsok; Kobayashi, Shogo; Marubashi, Shigeru; Eguchi, Hidetoshi; Tanemura, Masahiro; Kitagawa, Toru; Nagano, Hiroaki; Umeshita, Koji; Wakasa, Kenichi; Doki, Yuichiro; Mori, Masaki.

In: Oncology Reports, Vol. 24, No. 3, 09.2010, p. 613-620.

Research output: Contribution to journalArticle

Tomimaru, Y, Takeda, Y, Tatsumi, M, Kim, T, Kobayashi, S, Marubashi, S, Eguchi, H, Tanemura, M, Kitagawa, T, Nagano, H, Umeshita, K, Wakasa, K, Doki, Y & Mori, M 2010, 'Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas', Oncology Reports, vol. 24, no. 3, pp. 613-620. https://doi.org/10.3892/or-00000899
Tomimaru, Yoshito ; Takeda, Yutaka ; Tatsumi, Mitsuaki ; Kim, Tonsok ; Kobayashi, Shogo ; Marubashi, Shigeru ; Eguchi, Hidetoshi ; Tanemura, Masahiro ; Kitagawa, Toru ; Nagano, Hiroaki ; Umeshita, Koji ; Wakasa, Kenichi ; Doki, Yuichiro ; Mori, Masaki. / Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. In: Oncology Reports. 2010 ; Vol. 24, No. 3. pp. 613-620.
@article{e6ddcdfb46414ae487fc734fcfc0ff61,
title = "Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas",
abstract = "Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas presents in various histopathological stages from benign to malignant lesions. The differentiation between benign and malignant IPMN is important in order to determine the treatment of the patients. However, preoperative differentiation remains difficult. The aim of this study was to assess the utility of 2-[ 18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in preoperative differentiation of benign and malignant IPMN of the pancreas. In the present study we prospectively investigated 29 patients who underwent CT, FDG-PET, and surgery for IPMNs, followed by histopathological examination. The maximum standardized uptake value (SUVmax) was determined on FDG-PET, and differentiation of benign from malignant IPMN was tested using various SUVmax cut-off levels and various parameters derived from the CT. SUVmax was found to be significantly higher in malignant IPMNs (4.7±3.0) than that in benign IPMNs (1.8±0.3, P=0.0011). SUVmax values correlated with the histopathological types of IPMN (adenoma/borderline lesion/carcinoma in situ/invasive carcinoma) (Spearman rank correlation 0.865, P<0.0001). The specificity, sensitivity and accuracy values were best for SUVmax of 2.5 (100, 93, and 96{\%}, respectively). The combination of mural nodule, detected on CT, and SUVmax of 2.5 offered the best diagnosis of malignant IPMN. These results suggest that FDG-PET is useful for differentiation of malignant IPMN of the pancreas, and that it should be performed in combination with other conventional imaging modalities.",
author = "Yoshito Tomimaru and Yutaka Takeda and Mitsuaki Tatsumi and Tonsok Kim and Shogo Kobayashi and Shigeru Marubashi and Hidetoshi Eguchi and Masahiro Tanemura and Toru Kitagawa and Hiroaki Nagano and Koji Umeshita and Kenichi Wakasa and Yuichiro Doki and Masaki Mori",
year = "2010",
month = "9",
doi = "10.3892/or-00000899",
language = "English",
volume = "24",
pages = "613--620",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas

AU - Tomimaru, Yoshito

AU - Takeda, Yutaka

AU - Tatsumi, Mitsuaki

AU - Kim, Tonsok

AU - Kobayashi, Shogo

AU - Marubashi, Shigeru

AU - Eguchi, Hidetoshi

AU - Tanemura, Masahiro

AU - Kitagawa, Toru

AU - Nagano, Hiroaki

AU - Umeshita, Koji

AU - Wakasa, Kenichi

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2010/9

Y1 - 2010/9

N2 - Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas presents in various histopathological stages from benign to malignant lesions. The differentiation between benign and malignant IPMN is important in order to determine the treatment of the patients. However, preoperative differentiation remains difficult. The aim of this study was to assess the utility of 2-[ 18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in preoperative differentiation of benign and malignant IPMN of the pancreas. In the present study we prospectively investigated 29 patients who underwent CT, FDG-PET, and surgery for IPMNs, followed by histopathological examination. The maximum standardized uptake value (SUVmax) was determined on FDG-PET, and differentiation of benign from malignant IPMN was tested using various SUVmax cut-off levels and various parameters derived from the CT. SUVmax was found to be significantly higher in malignant IPMNs (4.7±3.0) than that in benign IPMNs (1.8±0.3, P=0.0011). SUVmax values correlated with the histopathological types of IPMN (adenoma/borderline lesion/carcinoma in situ/invasive carcinoma) (Spearman rank correlation 0.865, P<0.0001). The specificity, sensitivity and accuracy values were best for SUVmax of 2.5 (100, 93, and 96%, respectively). The combination of mural nodule, detected on CT, and SUVmax of 2.5 offered the best diagnosis of malignant IPMN. These results suggest that FDG-PET is useful for differentiation of malignant IPMN of the pancreas, and that it should be performed in combination with other conventional imaging modalities.

AB - Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas presents in various histopathological stages from benign to malignant lesions. The differentiation between benign and malignant IPMN is important in order to determine the treatment of the patients. However, preoperative differentiation remains difficult. The aim of this study was to assess the utility of 2-[ 18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in preoperative differentiation of benign and malignant IPMN of the pancreas. In the present study we prospectively investigated 29 patients who underwent CT, FDG-PET, and surgery for IPMNs, followed by histopathological examination. The maximum standardized uptake value (SUVmax) was determined on FDG-PET, and differentiation of benign from malignant IPMN was tested using various SUVmax cut-off levels and various parameters derived from the CT. SUVmax was found to be significantly higher in malignant IPMNs (4.7±3.0) than that in benign IPMNs (1.8±0.3, P=0.0011). SUVmax values correlated with the histopathological types of IPMN (adenoma/borderline lesion/carcinoma in situ/invasive carcinoma) (Spearman rank correlation 0.865, P<0.0001). The specificity, sensitivity and accuracy values were best for SUVmax of 2.5 (100, 93, and 96%, respectively). The combination of mural nodule, detected on CT, and SUVmax of 2.5 offered the best diagnosis of malignant IPMN. These results suggest that FDG-PET is useful for differentiation of malignant IPMN of the pancreas, and that it should be performed in combination with other conventional imaging modalities.

UR - http://www.scopus.com/inward/record.url?scp=77956298108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956298108&partnerID=8YFLogxK

U2 - 10.3892/or-00000899

DO - 10.3892/or-00000899

M3 - Article

C2 - 20664965

AN - SCOPUS:77956298108

VL - 24

SP - 613

EP - 620

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 3

ER -